News & Investors

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Aug 17, 2008
Aug 5, 2008
Cara Therapeutics, Inc. today announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and chronic pain. The drug candidate was safe and well-tolerated after intravenous infusion, and resulted in plasma levels of CR845 expected to be ...
Jul 24, 2008
Cara Therapeutics, Inc. announced today that it had closed on $12.3 million of additional funding to its original $24 million Series C financing which was completed in 2007. The round was led by new investor, Devon Park Bioventures, and included participation by Connecticut Innovations. Previous investors participating in the round included; As...
Jul 22, 2008
Cara Therapeutics, Inc. announced today that The United States Patent and Trademark Office has issued U.S. Patent No. 7,402,564 entitled “Synthetic Peptide Amides” under its Accelerated Examination Program. The application was filed on November 12, 2007 and covers Cara’s second generation, peripherally-selective kappa opioid...
Jun 25, 2008
Apr 28, 2008
Cara Therapeutics, Inc. today announced that it has initiated a Phase 1 clinical trial of its long-acting peripheral kappa opioid receptor agonist, CR845. The Phase 1a single-center clinical trial will evaluate the safety, tolerability, pharmacokinetic profile, and pharmacological activity of CR845 in a double-blind, randomized, placebo-controll...
Nov 28, 2006
Cara Therapeutics, Inc. announced today that it had closed on $19 million of its Series C financing. New investors participating in the round include MVM Life Science Partners and Alta Biopharma Partners, as well as previous investors Ascent Biomedical Ventures. In conjunction with the financing, Dr. Stephen Reeders, Managing Partner of MVM Life...
Mar 22, 2006
Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry and informatics products and services, today announced that Tripos Discovery Research Ltd. (TDR), based in Bude, England, has formed a new research collaboration with Cara Therapeutics, an emerging U.S. biotechnology company based in Tarrytown, N.Y. Cara is focused on d...
Jul 28, 2005
Cara Therapeutics, Inc. today announced results of a Phase 1 clinical trial for its peripherally acting kappa opioid agonist, CR665, under development for the treatment of postoperative pain. The drug candidate was safe and well-tolerated after intravenous infusion, and resulted in plasma levels of CR665 expected to be associated with clinical a...
Mar 24, 2005
Cara Therapeutics, Inc. announced today that it had initiated dosing in a Phase 1 clinical trial for CR665, its novel drug candidate for the treatment of postoperative pain. The single-dose protocol is scheduled to be completed in the second quarter of 2005. The study will evaluate the safety, tolerability and pharmacokinetic profile of ...
= add release to Briefcase